Despite attempts to acknowledge the borderline nature of some of these findings by introducing a “borderline” group in the ASCO guidelines for HER2 measurement in breast cancer [38], it is still unclear to what extent these tumors respond to anti-HER2 therapy. The gene discussed is ERBB2; the disease is breast carcinoma.